| Issue | Title | |
| Vol 10, No 1 (2017) | PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM | Abstract PDF (Rus) |
| N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova | ||
| Vol 15, No 1 (2022) | Perioperative pharmacotherapy for endoprosthetics: potential of chondroitin sulfate and glucosamine sulfate | Abstract PDF (Rus) |
| I. Yu. Torshin, T. B. Minasov, N. V. Zagorodniy, A. M. Lila, O. A. Gromova | ||
| Vol 14, No 1 (2021) | Perspectives of osteoarthritis prevention and therapy personification based on the analysis of comorbid background, genetic polymorphisms and microelement status | Abstract PDF (Rus) |
| I. Yu. Torshin, A. M. Lila, A. V. Naumov, I. S. Sardaryan, T. E. Bogacheva, T. R. Grishina, I. V. Gogoleva, O. A. Limanova, O. A. Gromova | ||
| Vol 5, No 1 (2012) | PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION | Abstract |
| R. Yagudina, A. Kulikov, B. Misikova | ||
| Vol 18, No 3 (2025) | Pharmaceutical information as an aspect of shaping patient behavior when choosing a pharmacy organization and self-medication | Abstract PDF (Rus) |
| M. S. Soboleva, S. V. Dyachenko | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia | Abstract |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic | Abstract PDF (Rus) |
| Yu. Sh. Gushchina, А. Yu. Abramov, Y. J. Haitham | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract PDF (Rus) |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment | Abstract |
| A. U. Kulikov, V. V. Babiy | ||
| Vol 10, No 1 (2017) | PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS | Abstract PDF (Rus) |
| A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract PDF (Rus) |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| Vol 9, No 2 (2016) | PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION | Abstract PDF (Rus) |
| T. V. Gaygolnik, I. V. Demko, E. N. Bochanova, A. Yu. Kraposhina, N. V. Gordeeva, I. A. Soloveva | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER | Abstract |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| Vol 8, No 1 (2015) | PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION | Abstract PDF (Rus) |
| M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia | Abstract PDF (Rus) |
| V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract |
| R. I. Yagudina, M. M. Murashko | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract PDF (Rus) |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| Vol 17, No 4 (2024) | Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system | Abstract PDF (Rus) |
| A. V. Rudakova, I. Z. Gaydukova | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION | Abstract |
| A. Yu. Kulikov, I. Yu. Zinchuk | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies | Abstract PDF (Rus) |
| K. A. Perova, D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, N. Z. Musina | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract PDF (Rus) |
| O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS | Abstract PDF (Rus) |
| E. E. Vidyakina, S. V. Malchikova | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation | Abstract PDF (Rus) |
| S. К. Zyryanov, I. N. Dyakov | ||
| Vol 7, No 3 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA | Abstract PDF (Rus) |
| A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova | ||
| Vol 7, No 2 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD | Abstract PDF (Rus) |
| A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin | ||
| Vol 13, No 2 (2020) | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation | Abstract PDF (Rus) |
| S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract PDF (Rus) |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract PDF (Rus) |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract PDF (Rus) |
| A. G. Tolkushin, N. L. Pogudina | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings | Abstract PDF (Rus) |
| M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract PDF (Rus) |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer | Abstract PDF (Rus) |
| N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov | ||
| Vol 16, No 4 (2023) | Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation | Abstract PDF (Rus) |
| M. V. Zhuravleva, K. A. Kokushkin, E. A. Luchinin, E. V. Luchinina, T. R. Kameneva, E. V. Kuznetsova, V. S. Krysanova, E. V. Makarova, L. G. Zhukova | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation | Abstract PDF (Rus) |
| R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova, I. Yu. Torshin | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract PDF (Rus) |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | Abstract PDF (Rus) |
| N. A. Avxentyev, M. Yu. Frolov | ||
| Vol 1, No 19 (2026) | Pharmacoeconomic and socioeconomic aspects of multiple sclerosis treatment in different countries | Abstract PDF (Rus) |
| S. S. Maslova | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic aspects of COVID-19 treatment | Abstract PDF (Rus) |
| I. V. Rogova, E. A. Zhidkova, I. A. Popova, A. V. Zaborovskiy, K. G. Gurevich | ||
| Vol 10, No 2 (2017) | PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY | Abstract PDF (Rus) |
| A. V. Rudakova, S. A. Protsenko, I. A. Koroleva | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract PDF (Rus) |
| D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract PDF (Rus) |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract PDF (Rus) |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| Vol 13, No 1 (2020) | Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract PDF (Rus) |
| S. K. Zyryanov, I. N. Diyakov | ||
| Vol 1, No 19 (2026) | Pharmacoeconomic evaluation of contemporary treatment, prevention, and screening strategies for melanoma: a review of evidence and implications for the Russian healthcare system | Abstract PDF (Rus) PDF (Rus) |
| V. M. Polezhaeva, D. S. Beloglazova, E. S. Trunina, A. A. Grinina, A. M. Burmagina, D. N. Gamzova, Yu. M. Kirdyashkina, А. N. Novikov, A. A. Khudiyarov, L. Aydasheva, D. F. Vorobyev, D. R. Khayrutdinova | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract PDF (Rus) |
| S. К. Zyryanov, I. N. Dyakov | ||
| Vol 8, No 4 (2015) | PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER | Abstract PDF (Rus) |
| D. A. Zhukov | ||
| Vol 10, No 2 (2017) | PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA | Abstract PDF (Rus) |
| M. Yu. Frolov, O. V. Shatalova | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT | Abstract PDF (Rus) |
| N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer | Abstract PDF (Rus) |
| Yu. Yu. Petukhova, E. V. Eliseeva, M. V. Volkov, O. N. Li, A. G. Petukhova | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract |
| A. U. Kulikov | ||
| 351 - 400 of 585 Items | << < 3 4 5 6 7 8 9 10 11 12 > >> | |
Browse Title Index
Popular articles
Vol 17, No 2 (2024)
Vol 17, No 3 (2024)
Vol 10, No 1 (2017)
Vol 16, No 3 (2023)
Vol 16, No 4 (2023)
Vol 14, No 4 (2021)
Keywords
COVID-19
artificial intelligence
budget impact
budget impact analysis
chemotherapy
chondroitin sulfate
clinical and economic analysis
cost minimization analysis
cost-effectiveness analysis
evidence-based medicine
glucosamine sulfate
health technology assessment
oncology
pharmaceutical market
pharmacoeconomic analysis
pharmacoeconomic modeling
pharmacoeconomics
pharmacoepidemiology
pharmacoinformatics
quality of life
systematic review
Publisher: IRBIS LLC
24 Chechersky St., Moscow 117042
Phone: +7 (495) 649 54 95
Email: digevskaya@irbis-1.ru
